PriceTargets.com logo

10x Genomics - TXG Stock Price Target and Predictions

  • Consensus Rating: Moderate Buy
  • Consensus Price Target: $29.19
  • Forecasted Upside: 118.80%
  • Number of Analysts: 17
  • Breakdown:
  • 1 Sell Ratings
  • 7 Hold Ratings
  • 8 Buy Ratings
  • 1 Strong Buy Ratings
$13.34 As of 11/15/2024 01:00 AM ET
▼ -0.78 (-5.52%)

This chart shows the closing price for TXG by one month, three months, or twelve months.

Skip Closing Price Chart
1 month | 3 months | 12 months
Get New 10x Genomics Analyst Ratings Delivered To Your Inbox
Sign-up to receive the latest news and ratings for TXG and its competitors with Analyst Ratings Network’s free daily newsletter.

Analyst Price Target for TXG

Analyst Price Target is $29.19
▲ +118.80% Upside Potential
This price target is based on 17 analysts offering 12 month price targets for 10x Genomics in the last 3 months. The average price target is $29.19, with a high forecast of $60.00 and a low forecast of $14.00. The average price target represents a 118.80% upside from the last price of $13.34.

This chart shows the closing price for TXG for the last year in relation to the current analyst high, average, and low pricetarget.

Read Analyst Price Chart DescriptionSkip Analyst Price Chart




Current Consensus is Moderate Buy

The current consensus among 17 polled investment analysts is to moderate buy stock in 10x Genomics. This rating has held steady since August 2024, when it changed from a Hold consensus rating.

Past Monthly Recommendations

Move your mouse over past months for details

Read Past Recommendations DescriptionSkip Past Price Target Consensus Chart
  • 0 strong buy ratings
  • 7 buy ratings
  • 2 hold ratings
  • 2 sell ratings
Ratings as of
5/26/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 1 sell ratings
Ratings as of
8/24/2023
  • 0 strong buy ratings
  • 7 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
11/22/2023
  • 0 strong buy ratings
  • 8 buy ratings
  • 1 hold ratings
  • 0 sell ratings
Ratings as of
2/20/2024
  • 0 strong buy ratings
  • 8 buy ratings
  • 3 hold ratings
  • 1 sell ratings
Ratings as of
5/20/2024
  • 0 strong buy ratings
  • 5 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
8/18/2024
  • 1 strong buy ratings
  • 7 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
10/17/2024
  • 1 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 1 sell ratings
Ratings as of
11/16/2024

Latest Recommendations

  • 1 strong buy ratings
  • 8 buy ratings
  • 7 hold ratings
  • 1 sell ratings

Display Ratings By
DateBrokerageActionRatingPrice TargetDetails
11/1/2024BarclaysLower TargetOverweight ➝ Overweight$21.00 ➝ $19.00
10/30/2024CitigroupLower TargetBuy ➝ Buy$35.00 ➝ $23.00
10/30/2024JPMorgan Chase & Co.Lower TargetNeutral ➝ Neutral$20.00 ➝ $14.00
10/30/2024The Goldman Sachs GroupLower TargetSell ➝ Sell$16.00 ➝ $14.00
10/30/2024UBS GroupLower TargetNeutral ➝ Neutral$25.00 ➝ $20.00
10/15/2024BarclaysLower TargetOverweight ➝ Overweight$24.00 ➝ $21.00
10/10/2024StephensReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
10/10/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$32.00 ➝ $20.00
9/4/2024StephensReiterated RatingOverweight ➝ Overweight$30.00 ➝ $30.00
9/3/2024Leerink PartnrsUpgradeStrong-Buy
9/3/2024Leerink PartnersInitiated CoverageOutperform$35.00
8/13/2024UBS GroupLower TargetNeutral ➝ Neutral$30.00 ➝ $25.00
8/13/2024Morgan StanleyLower TargetOverweight ➝ Overweight$50.00 ➝ $46.00
7/23/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$50.00 ➝ $32.00
7/22/2024Jefferies Financial GroupUpgradeHold ➝ Buy$24.00 ➝ $24.00
7/18/2024Bank of AmericaLower TargetNeutral ➝ Neutral$36.00 ➝ $25.00
7/18/2024JPMorgan Chase & Co.DowngradeOverweight ➝ Neutral$40.00 ➝ $20.00
7/16/2024Stifel NicolausLower TargetBuy ➝ Buy$53.00 ➝ $25.00
7/10/2024Deutsche Bank AktiengesellschaftDowngradeBuy ➝ Hold$55.00 ➝ $25.00
7/9/2024The Goldman Sachs GroupLower TargetSell ➝ Sell$26.00 ➝ $16.00
6/28/2024BarclaysLower TargetOverweight ➝ Overweight$36.00 ➝ $24.00
6/27/2024Wolfe ResearchReiterated RatingOutperform ➝ Peer Perform
6/25/2024GuggenheimReiterated RatingBuy ➝ Neutral
6/3/2024Jefferies Financial GroupInitiated CoverageHold$24.00
5/1/2024UBS GroupLower TargetNeutral ➝ Neutral$52.00 ➝ $30.00
5/1/2024The Goldman Sachs GroupLower TargetSell ➝ Sell$30.00 ➝ $26.00
5/1/2024Bank of AmericaLower TargetNeutral ➝ Neutral$45.00 ➝ $36.00
5/1/2024Stifel NicolausLower TargetBuy ➝ Buy$63.00 ➝ $53.00
5/1/2024TD CowenDowngradeBuy ➝ Hold$57.00 ➝ $32.00
4/29/2024Canaccord Genuity GroupLower TargetBuy ➝ Buy$65.00 ➝ $50.00
4/18/2024Deutsche Bank AktiengesellschaftLower TargetBuy ➝ Buy$60.00 ➝ $55.00
4/10/2024BarclaysLower TargetOverweight ➝ Overweight$55.00 ➝ $45.00
2/16/2024Stifel NicolausLower TargetBuy ➝ Buy$68.00 ➝ $63.00
1/25/2024BarclaysBoost TargetOverweight ➝ Overweight$45.00 ➝ $55.00
12/14/2023GuggenheimInitiated CoverageBuy$60.00
12/13/2023Wolfe ResearchInitiated CoverageOutperform$55.00
12/12/2023Bank of AmericaUpgradeUnderperform ➝ Neutral$36.00 ➝ $54.00
9/29/2023BarclaysLower TargetOverweight ➝ Overweight$66.00 ➝ $47.00
9/19/2023Canaccord Genuity GroupReiterated RatingBuy ➝ Buy$70.00
8/7/2023Morgan StanleyReiterated RatingOverweight ➝ Overweight$65.00
8/4/2023BarclaysBoost TargetOverweight ➝ Overweight$65.00 ➝ $66.00
8/4/2023CitigroupBoost TargetBuy ➝ Buy$65.00 ➝ $75.00
5/10/2023BarclaysInitiated CoverageOverweight$65.00
5/4/2023Stifel NicolausBoost Target$57.00 ➝ $68.00
3/30/2023StephensInitiated CoverageOverweight$65.00
2/16/2023Canaccord Genuity GroupBoost TargetBuy$55.00 ➝ $58.00
2/16/2023Morgan StanleyBoost TargetOverweight$64.00 ➝ $65.00
2/16/2023Stifel NicolausBoost Target$53.00 ➝ $57.00
2/16/2023CowenBoost TargetOutperform$52.00 ➝ $57.00
2/2/2023UBS GroupInitiated CoverageNeutral$50.00
12/13/2022Deutsche Bank AktiengesellschaftInitiated CoverageBuy$50.00
11/4/2022Morgan StanleyLower TargetOverweight$70.00 ➝ $64.00
11/3/2022JPMorgan Chase & Co.Lower Target$65.00 ➝ $55.00
10/13/2022The Goldman Sachs GroupLower TargetSell$35.00 ➝ $25.00
8/18/2022The Goldman Sachs GroupDowngradeNeutral ➝ Sell$55.00 ➝ $35.00
8/15/2022CowenBoost Target$55.00
8/10/2022Morgan StanleyLower TargetOverweight$100.00 ➝ $70.00
8/9/2022CowenBoost Target$50.00 ➝ $55.00
8/9/2022CowenBoost Target$50.00 ➝ $55.00
8/9/2022CitigroupLower Target$100.00 ➝ $65.00
7/25/2022Canaccord Genuity GroupInitiated CoverageBuy
7/15/2022CowenLower TargetOutperform$90.00 ➝ $50.00
7/15/2022CowenLower Target$90.00 ➝ $50.00
7/15/2022William BlairDowngradeOutperform ➝ Market Perform
7/15/2022Bank of AmericaDowngradeNeutral ➝ Underperform$35.00
7/14/2022The Goldman Sachs GroupLower TargetNeutral$80.00 ➝ $60.00
5/5/2022CitigroupLower Target$150.00 ➝ $100.00
4/13/2022The Goldman Sachs GroupLower TargetNeutral$95.00 ➝ $85.00
2/17/2022CowenLower Target$205.00 ➝ $145.00
2/17/2022CitigroupLower TargetBuy$175.00 ➝ $150.00
11/4/2021Morgan StanleyLower TargetOverweight$215.00 ➝ $205.00
9/16/2021National Bank FinancialInitiated CoverageSector Perform$24.00
9/14/2021Bank of AmericaDowngradeBuy ➝ Neutral$180.00
8/5/2021CitigroupLower TargetBuy$240.00 ➝ $220.00
3/15/2021William BlairInitiated CoverageOutperform
2/25/2021Morgan StanleyBoost TargetOverweight$145.00 ➝ $215.00
2/18/2021CitigroupBoost Target$195.00 ➝ $240.00
2/18/2021CowenBoost TargetOutperform$155.00 ➝ $200.00
2/18/2021JPMorgan Chase & Co.Boost TargetOverweight$160.00 ➝ $195.00
12/16/2020Smith Barney CitigroupBoost Target$165.00 ➝ $195.00
12/2/2020The Goldman Sachs GroupInitiated CoverageNeutral$150.00
11/11/2020Smith Barney CitigroupBoost Target$120.00 ➝ $165.00
11/11/2020Morgan StanleyBoost TargetOverweight$135.00 ➝ $145.00
9/16/2020Bank of AmericaBoost TargetBuy$109.00 ➝ $138.00
9/15/2020JPMorgan Chase & Co.Boost TargetOverweight$110.00 ➝ $140.00
9/9/2020Morgan StanleyInitiated CoverageOverweight$135.00
8/12/2020JPMorgan Chase & Co.Boost TargetOverweight$95.00 ➝ $110.00
7/20/2020Bank of AmericaBoost TargetBuy$91.00 ➝ $105.00
7/9/2020Stifel NicolausInitiated CoverageBuy$105.00
5/12/2020CitigroupBoost TargetBuy$90.00 ➝ $100.00
5/12/2020JPMorgan Chase & Co.Boost TargetOverweight$90.00 ➝ $95.00
5/12/2020CowenBoost TargetOutperform$68.00 ➝ $85.00
4/20/2020CitigroupBoost TargetBuy$75.00 ➝ $90.00
3/20/2020CitigroupLower TargetBuy$100.00 ➝ $75.00
3/5/2020GuggenheimInitiated CoverageBuy$96.00
2/19/2020JPMorgan Chase & Co.Reiterated RatingOverweight$65.00 ➝ $95.00
1/6/2020CitigroupInitiated CoverageBuy
12/20/2019Evercore ISIInitiated CoverageBuy$62.00
(Data available from 11/17/2019 forward)

News Sentiment Rating

0.32 (Hold)

Our news sentiment rating is based on the average sentiment of articles about this company published in the media in the last 30 days of headlines and can range from 2 (very positive sentiment) to -2 (very negative sentiment).

News Sentiment Over Time

Move your mouse over past months for details

Skip to Current Sentiment Summary
  • 6 very positive mentions
  • 7 positive mentions
  • 2 negative mentions
  • 0 very negative mentions
Mentions as of
4/21/2024
  • 6 very positive mentions
  • 15 positive mentions
  • 7 negative mentions
  • 1 very negative mentions
Mentions as of
5/21/2024
  • 13 very positive mentions
  • 2 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
6/20/2024
  • 9 very positive mentions
  • 9 positive mentions
  • 6 negative mentions
  • 0 very negative mentions
Mentions as of
7/20/2024
  • 9 very positive mentions
  • 19 positive mentions
  • 3 negative mentions
  • 0 very negative mentions
Mentions as of
8/19/2024
  • 10 very positive mentions
  • 9 positive mentions
  • 0 negative mentions
  • 0 very negative mentions
Mentions as of
9/18/2024
  • 17 very positive mentions
  • 23 positive mentions
  • 4 negative mentions
  • 0 very negative mentions
Mentions as of
10/18/2024
  • 8 very positive mentions
  • 20 positive mentions
  • 4 negative mentions
  • 1 very negative mentions
Mentions as of
11/17/2024

Current Sentiment

  • 8 very positive mentions
  • 20 positive mentions
  • 4 negative mentions
  • 1 very negative mentions

Recent Stories by Sentiment

Very Negative

Negative

Positive

Very Positive

10x Genomics logo
10x Genomics, Inc., a life science technology company, develops and sells instruments, consumables, and software for analyzing biological systems in the America, Europe, the Middle East, Africa, China, and the Asia Pacific. The company provides chromium, chromium connect, and chromium controller instruments, microfluidic chips, slides, reagents, and other consumables products. Its single cell solutions runs on its chromium instruments, which include single cell gene expression for measuring gene activity and networks on a cell-by-cell basis; single cell gene expression flex; single cell immune profiling used to study the immune system; single cell Assay for Transposase Accessible Chromati (ATAC) solution to understand the epigenetic state; and single cell multiome ATAC + gene expression which enables simultaneous interrogation of both the RNA and chromatin accessibility, using ATAC in a single cell. The company also provides Visium platform which enables researchers to understand the spatial positions of biological analytes within tissues at high resolution; and Xenium platform for in situ analysis. It serves various academic, government, biopharmaceutical, biotechnology, and other institutions. The company was formerly known as 10X Technologies, Inc. and changed its name to 10x Genomics, Inc. in November 2014. 10x Genomics, Inc. was incorporated in 2012 and is headquartered in Pleasanton, California.
Read More

Today's Range

Now: $13.34
Low: $13.30
High: $14.07

50 Day Range

MA: $18.42
Low: $13.34
High: $23.48

52 Week Range

Now: $13.34
Low: $13.30
High: $57.90

Volume

2,891,358 shs

Average Volume

1,968,960 shs

Market Capitalization

$1.61 billion

P/E Ratio

N/A

Dividend Yield

N/A

Beta

1.87

Frequently Asked Questions

What sell-side analysts currently cover shares of 10x Genomics?

The following sell-side analysts have issued reports on 10x Genomics in the last year: Bank of America Co., Barclays PLC, Canaccord Genuity Group Inc., Citigroup Inc., Deutsche Bank Aktiengesellschaft, Guggenheim, Jefferies Financial Group Inc., JPMorgan Chase & Co., Leerink Partners, Leerink Partnrs, Morgan Stanley, Stephens, Stifel Nicolaus, TD Cowen, The Goldman Sachs Group, Inc., UBS Group AG, and Wolfe Research.
View the latest analyst ratings for TXG.

What is the current price target for 10x Genomics?

0 Wall Street analysts have set twelve-month price targets for 10x Genomics in the last year. Their average twelve-month price target is $29.19, suggesting a possible upside of 118.8%. Guggenheim has the highest price target set, predicting TXG will reach $60.00 in the next twelve months. The Goldman Sachs Group, Inc. has the lowest price target set, forecasting a price of $14.00 for 10x Genomics in the next year.
View the latest price targets for TXG.

What is the current consensus analyst rating for 10x Genomics?

10x Genomics currently has 1 sell rating, 7 hold ratings, 8 buy ratings and 1 strong buy rating from Wall Street analysts. The stock has a consensus analyst rating of "Moderate Buy."
View the latest ratings for TXG.

What other companies compete with 10x Genomics?

Other companies that are similar to 10x Genomics include Cytek Biosciences, Standard BioTools, Pacific Biosciences of California, EyePoint Pharmaceuticals and Quanterix. Learn More about companies similar to 10x Genomics.

How do I contact 10x Genomics' investor relations team?

10x Genomics' physical mailing address is 6230 STONERIDGE MALL ROAD, PLEASANTON CA, 94588. The company's listed phone number is 925-401-7300 and its investor relations email address is [email protected]. The official website for 10x Genomics is www.10xgenomics.com. Learn More about contacing 10x Genomics investor relations.